project id: TCGA-KIRP; case submitter id: TCGA-4A-A93Y; analyte type: DNA; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.85; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.13; rna integrity number: 7.2; age at index: 63; days to birth: -23226; ethnicity: not hispanic or latino; gender: female; race: black or african american; vital status: Alive; year of birth: 1950; age at diagnosis: 23226; ajcc clinical m: M0; ajcc clinical n: N0; ajcc clinical stage: Stage II; ajcc clinical t: T2b; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage II; ajcc pathologic t: T2b; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 352.0; icd 10 code: C64.1; last known disease status: not reported; morphology: 8260/3; primary diagnosis: Papillary adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Kidney, NOS; synchronous malignancy: No; tissue or organ of origin: Kidney, NOS; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; cigarettes per day: 1.2328767123287672; pack years smoked: 22.5; years smoked: 15.0; is ffpe: false; composition: Not Reported; days to collection: 41; days to sample procurement: 0; initial weight: 910.0; portion submitter id: TCGA-4A-A93Y-01A-11; percent lymphocyte infiltration: 6.0; percent monocyte infiltration: 4.0; percent necrosis: 5.0; percent neutrophil infiltration: 2.0; percent normal cells: 0.0; percent stromal cells: 55.0; percent tumor cells: 40.0; percent tumor nuclei: 75.0;